T-cell-targeted immunotherapy in neurofibromatosis type 2-related vestibular schwannoma: current evidence and future direction

NF2-related vestibular schwannomas are notoriously difficult to manage and often lead to profound hearing loss; emerging immunotherapy options could eventually change the treatment landscape for this population.